Antiplatelet and anticoagulative medication during shockwave lithotripsy.
Journal of endourology · 2014 · Vol. 28 · Issue 9 · 1034-9
Academy Summary
Schnabel and colleagues reviewed the evidence regarding antiplatelet and anticoagulant medication in patients undergoing shock wave lithotripsy (SWL), with particular attention to balancing SWL-related bleeding risk against the cardiovascular consequences of interrupting necessary antithrombotic therapy.
The authors performed a structured Medline/PubMed literature search across urological and cardiovascular literature. They found that evidence specifically addressing SWL in patients with acquired or pathological bleeding risk was limited, largely retrospective, non-standardized, and generally low quality.
Historically, uncorrected bleeding disorders and ongoing anticoagulation have been considered contraindications to SWL because shock waves can produce renal vascular injury and potentially lead to renal or perirenal haematoma.
However, the review emphasized an equally important competing risk: unnecessary interruption of medically essential antiplatelet or anticoagulant treatment can result in serious cardiovascular or thromboembolic events.
The authors specifically questioned whether low-dose aspirin should always be regarded as an absolute contraindication to SWL, suggesting that selected patients might be considered for treatment after individualized assessment rather than automatically being excluded.
The paper therefore moved the discussion from a simple medication-based exclusion rule toward an individualized balance of:
Bleeding risk + Cardiovascular risk + Drug indication + Treatment alternatives
Current EAU guidance continues this risk-based approach. SWL is classified as a high-bleeding-risk stone procedure, and patients receiving antithrombotic therapy should be assessed together with the prescribing physician. When therapy cannot safely be interrupted and active stone removal is necessary, ureteroscopy is generally preferred because of its lower bleeding morbidity.
Comments & Discussion0 comments
Discuss the publication's evidence, limitations and practical relevance. Please do not include identifiable patient information or individual medical advice.
No comments yet. Start the discussion.
Please log in to join the discussion.
